Abstract: FR-PO1058
Effect of Dapagliflozin on Kidney Function in Kidney Transplant Recipients: Six-Month Follow-Up
Session Information
- Transplantation: Clinical - Pharmacology and Nonkidney Solid Organ Transplants
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 2102 Transplantation: Clinical
Authors
- Andrade-Sierra, Jorge, Universidad de Guadalajara Centro Universitario de Ciencias de la Salud, Guadalajara, Jal., Mexico
- Monroy, Celeste Araceli, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jal., Mexico
- Rojas-Campos, Enrique, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jal., Mexico
- Aguilar Fletes, Laura Elizabeth, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jal., Mexico
- Palacios, Alicia Daniela, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jal., Mexico
- Evangelista-Carrillo, Luis Alberto, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jal., Mexico
- Cerrillos, Jose Ignacio, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jal., Mexico
- Medina Perez, Miguel, Universidad de Guadalajara Centro Universitario de Ciencias de la Salud, Guadalajara, Jal., Mexico
Background
The use of sodium-glucose cotransporter type 2 (iSGLT2) inhibitors and its beneficial effects in kidney transplant recipients (KTR) are not supported by sufficient evidence. Our purpose was compare the effect of dapagliflozin in the renal function in KTR.
Methods
From September 2024 to March 2025, we did a single-center, open-label, randomized study with 54 KTR. Nevertheless 33 of these patients made it through the first six months of follow-up. Patients in the intervention group started taking dapagliflozin (10 mg/day) one month after their transplants. Their results were compared to those of patients who did not receive SGLT2 inhibitors.
Results
The mean age was 35 years (SD 8.4); 38.6% men. Baseline mGFR was 74 ml/min/1.73 (SD 23), no difference in mGFR was demonstrated in both groups with intervention group mGFR at 6 months of 76.52 ml/min/1.73 vs control group mGFR at 6 months of 79.13 ml/min/1.73 (p= 0.72). There was no difference between albuminuria excretions between both groups (p=0.76).
Conclusion
The intervention group showed a stable glomerular filtration rate and proteinuria comparable to the control group. We need more follow-up time and to analyze the histopathological results of the biopsies to strengthen our results.
| Variable | Dapagliflozin n=18 | Control n =15 | P Value |
| mGFR baseline | 70 ml/min | 79 ml/min | 0.33 |
| mGFR 6 month | 76 ml/mim | 79 ml/min | 0.72 |
| Cr baseline (mg/dl) | 1.3 mg/dL | 1.2 mg/dL | 0.70 |
| Cr 6 month (mg/dl) | 1.2 mg/dL | 1.1 mg/dL | 0.83 |
| Glucose baseline | 101 mg/dL | 96 mg/dL | 0.60 |
| Glucosa 6 month | 84 mg/dL | 92 mg/dL | 0.031 |